IsleNova is actively advancing islet cell therapeutics through focused research and development programs that enhance both current autologous therapies and future regenerative solutions.
Our research programs are designed to push the boundaries of what is possible in islet cell therapy — improving outcomes for patients today while building the scientific foundation for next-generation regenerative medicine tomorrow. We focus on programs with clear translational pathways from bench to bedside.
We are conducting ongoing studies to improve islet recovery and function from stressed and diseased pancreatic organs. This includes refining isolation techniques and developing advanced benchmark assessments and predictive models that better correlate islet characteristics with long-term transplant success.
We are developing proprietary methods to harvest and characterize pancreatic progenitor cells capable of regenerating all components of pancreatic tissue and graft support — including parenchymal, exocrine, and endocrine. These "self" cells represent a promising approach for targeted regeneration, both in vivo and ex vivo.
Our R&D programs are designed with specific patient populations in mind — addressing significant unmet need across multiple pancreatic conditions.
Operational clinical islet processing supporting surgical teams performing total pancreatectomy with islet autotransplantation.
Advanced isolation protocols and predictive models for improved islet yield and viability from stressed and diseased tissue.
Proprietary progenitor cell harvesting, tissue banking, and directed differentiation toward autologous cell replacement therapy.
IsleNova is an early-stage R&D company. Pipeline programs are in active development. Timelines are subject to regulatory, funding, and scientific milestones.
We welcome collaboration with academic institutions, clinical partners, and investors aligned with our mission to advance islet cell therapeutics.